Kymera Therapeutics (KYMR) Non Operating Income (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Non Operating Income data on file, last reported at $14.9 million in Q1 2026.

• Non Operating Income for Q1 2026 came in at $14.9 million, up 68.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $44.1 million (up 18.14% YoY), and the FY2025 annual result was $38.0 million, up 0.72% from the prior year.
• Non Operating Income improved to $14.9 million in Q1 2026 per KYMR's latest filing, from $10.9 million in the prior quarter.
• Over five years, Non Operating Income peaked at $14.9 million in Q1 2026 and troughed at $249000.0 in Q1 2022.
• A 5-year average of $6.8 million and a median of $7.9 million in 2025 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2022 and 2025: Non Operating Income jumped 3905.32% in 2022, then declined 10.38% in 2025.
• A 5-year view of Non Operating Income shows it stood at $3.8 million in 2022, then jumped by 31.31% to $4.9 million in 2023, then jumped by 102.33% to $10.0 million in 2024, then advanced by 9.12% to $10.9 million in 2025, then soared by 36.69% to $14.9 million in 2026.
• Business Quant data shows KYMR's Non Operating Income at $14.9 million in Q1 2026, $10.9 million in Q4 2025, and $10.3 million in Q3 2025.